Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

23rd April in Biotech/pharma of MV History

By

PrintPRINT

These articles were published on Minyanville.com on 23rd April in History. Checkout how time flies, enjoy reading!

Ardea Biosciences and Sirius XM Radio Among Most Active Stocks in Pre-Market Today

on Apr 23, 2012 9:25 am by Christopher Witrak

The three most active stocks in pre-market trading on the Nasdaq were Ardea Biosciences (RDEA), Sirius XM Radio (SIRI), and Amylin Pharmaceuticals (AMLN) as of 9:00 a.m. Investors traded 9,709,364 shares of Ardea Biosciences, which was up $10.69, or 51.30%. Shares of Ardea skyrocketed on the news this morning that AstraZeneca (AZN) acquired Ardea for $32 a share. AstraZeneca valued the compa... Read More


11 Health-Care Names Poised for Gains

on Apr 23, 2012 11:20 am by MoneyShow.com

Kate Stalter: I'm speaking with Ramesh Gulati of Gulati Asset Management. Ramesh, welcome to Daily Guru. I understand that you have some thoughts today on some health-care sector names to discuss. Ramesh Gulati: Just before I start, a quick disclosure. Gulati Asset Management and its clients may be long or short in any of the names that are talked about in this article. Please don&rsq... Read More


Best of the Blogs: Wal-Mart Beats NewsCorp for Most Damaging Public Scandal

on Apr 23, 2012 11:40 am by Kathleen Culliton

This column highlights the most interesting and useful business and financial commentary from around the Web each day. Use our comments section to post your own suggestions for blog content that you've read or written. Huffington Post: Carl Pope Link: Walmart's Criminal Problems - Much Bigger Than NewsCorp's "OK, we now know that W... Read More


Amylin, Ardea Biosciences Show Brisk Pace for Biotech Drug Deals

on Apr 23, 2012 1:30 pm by Brett Chase

The pace of biotech drug takeovers is picking up again after a burst of deals earlier this year. Big UK drugmaker AstraZeneca (AZN) agreed to pay about $1.26 billion, or $32 per share, in cash to take over Ardea Biosciences (RDEA) of San Diego. AstraZeneca would gain an experimental gout drug that is in the late stages of development. Ardea also licensed an experimental cancer treatment to Baye... Read More


Best of the Blogs, Emerging Markets: China's Poisonous Drugs

on Apr 23, 2012 5:20 pm by Kathleen Culliton

This column highlights the most interesting and useful business and financial commentary on emerging markets from around the Web every Monday. Wall Street Journal: China Real Time Report Link: More Arrests in China Toxic Drug Capsule Scandal "Chinese officials have arrested nine people and detained 45 others allegedly tied to a recent product safet... Read More


Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

on Apr 23, 2013 11:55 am by David Miller

If I don't miss my guess, Medivation (NASDAQ:MDVN) shares will come under pressure today based upon an 8-K it filed on Monday. The decline, if it happens, reflects a basic lack of understanding of how long prostate cancer drug development takes. Since Medivation's Xtandi is the best-in-class drug for prostate cancer, any serious decline in Medivation's shares may make for a buyin... Read More
< Previous
  • 1
Next >
PrintPRINT
 
Featured Videos

WHAT'S POPULAR IN THE VILLE